SCHEDULE: Balyasny Asset Management Boosts Verastem Stake to 9.29%

Balyasny Asset Management and its affiliates reported a 9.29% beneficial ownership stake in Verastem Inc., totaling 5,718,190 shares.

Summary

• Balyasny Asset Management L.P. and its affiliated entities (BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny) collectively reported beneficial ownership of 5,718,190 shares of Verastem Inc. Common Stock.
• This represents approximately 9.29% of Verastem Inc.'s outstanding Common Stock.
• The ownership includes 1,571,428 shares of Common Stock issuable upon the exercise of Warrants.
• The calculation is based on 61,545,270 shares outstanding as of August 7, 2025, as reported in Verastem Inc.'s Form 10-Q.
• The shares are held by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P.
• The acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of Verastem Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment in Verastem Inc. by a reputable asset manager, which is generally a positive signal for the company's stock. The explicit statement that the acquisition is not for control purposes reduces potential concerns about activist intervention.

Positives

• Significant institutional investor, Balyasny Asset Management, holds a substantial stake, potentially indicating confidence in Verastem Inc.'s long-term prospects.
• The filing explicitly states the acquisition is for ordinary course of business, not for control, suggesting a passive, investment-oriented position.

Future Outlook

NA

Industry Context

The increased stake by a prominent asset manager like Balyasny Asset Management in a biotechnology company like Verastem Inc. could signal growing institutional interest in the sector or specific confidence in Verastem's pipeline or strategic direction, especially given the capital-intensive nature of biotech R&D.

Comparison to Industry Standards

• A 9.29% stake by a single institutional investor group is a significant position, often seen as a strong vote of confidence.
• Such a substantial holding by a well-known asset manager like Balyasny Asset Management is generally viewed positively within the investment community, aligning with trends of institutional investors building meaningful positions in promising biotech firms.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator of confidence, potentially leading to increased share price stability or appreciation.
• Management: The passive nature of the investment (not for control) suggests Balyasny is not seeking to influence management decisions directly, allowing current management to continue their strategy.

Key Dates

Recommendation

The filing reveals a substantial, passive stake by Balyasny Asset Management, indicating institutional confidence in Verastem Inc. This is a positive signal, but without additional financial or operational updates from the company, a 'hold' recommendation is appropriate. Investors should monitor future company performance and Balyasny's continued involvement for further insights.

Keywords

Verastem Inc., Balyasny Asset Management, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Management, Equity Stake